


Supplementary Figure 1





CD4⁺CD25⁺CD127^{-/low}CD45RA⁺FoxP3⁺ cells






Proportions of circulating CD4⁺CD25⁺CD127^{-/low}CD45RA⁺FoxP3⁺ cells and their FoxP3 expression. **(a)**: Comparison of CD4⁺CD25⁺CD127^{-/low}CD45RA⁺FoxP3⁺ cells between patients with acute AOSD and healthy controls (HC). **(b)**: Differences in the proportions of CD4⁺CD25⁺CD127^{-/low}CD45RA⁺FoxP3⁺ cells in 6 patients between the acute and remission phases of AOSD. The Mann-Whitney U test was used for comparison between acute AOSD patients and HC. The Wilcoxon signed ranked test was used for comparison between acute and remission phases in 6 AOSD patients.

Supplementary Figure 2

(a)



(b)




Supplementary Figure 2

Intracellular expression of effector cytokines in $CD4^+CD25^+CD127^{-/low}CD45RA^+FoxP3^+$ cells .


(a): (upper panels) Representative histograms of IFN- γ , IL-17, and IL-4 expression in $CD4^+CD25^+CD127^{-/low}CD45RA^+FoxP3^+$ cells. (lower bar graphs) Comparisons of the MFI of IFN- γ , IL-17, and IL-4 in $CD4^+CD25^+CD127^{-/low}CD45RA^+FoxP3^+$ cells between acute AOSD and HC. **(b):** Differences in the MFI of IFN- γ , IL-17, and IL-4 in $CD4^+CD25^+CD127^{-/low}CD45RA^+FoxP3^+$ cells from 6 patients between acute and remission phases. The Mann-Whitney U test was used for comparisons between acute AOSD patients and HC. The Wilcoxon signed ranked test was used for comparison between acute and remission phases in 6 AOSD patients.

Supplementary Figure 3

(a)



(b)



Supplementary Figure 3


Intracellular expression of transcription factors in CD4⁺CD25⁺CD127^{-/low}CD45RA⁺FoxP3⁺ cells .

(a): (upper panels) Representative histograms of T-bet, ROR γ t, and GATA3 expression in CD4⁺CD25⁺CD127^{-/low}CD45RA⁺FoxP3⁺ cells. (lower bar graphs) Comparisons of the MFI of T-bet, ROR γ t, and GATA3 in CD4⁺CD25⁺CD127^{-/low}CD45RA⁺FoxP3⁺ cells between acute AOSD and HC.

(b): Differences in the MFI of T-bet, ROR γ t, and GATA3 in CD4⁺CD25⁺CD127^{-/low}CD45RA⁺FoxP3⁺ cells from 6 patients between acute and remission phases. The Mann-Whitney U test was used for comparisons between acute AOSD patients and HC. The Wilcoxon signed ranked test was used for comparison between acute and remission phases in 6 AOSD patients.

Supplementary Figure 4


In $CD4^+CD25^+CD127^{-/low}CD45RA^+$ cells



FoxP3 expression in $CD4^+CD25^+CD127^{-/low}CD45RA^+$ cells.

(a): Comparison of the median fluorescence index (MFI) of FoxP3 in $CD4^+CD25^+CD127^{-/low}CD45RA^+$ cells between patients with acute AOSD and HC (upper panels). **(b)**: Differences in the MFI of FoxP3 in $CD4^+CD25^+CD127^{-/low}CD45RA^+$ cells in 6 patients between the acute and remission phases of AOSD. The Mann-Whitney U test was used for comparison between acute AOSD patients and HC. The Wilcoxon signed ranked test was used for comparison between acute and remission phases in 6 AOSD patients.

Supplementary Figure 5



Significant results of effector cytokine expression in $CD4^+CD25^+FoxP3^+$ cells (Tregs) between AOSD patients with and without clinical features.

(a): The median fluorescence index (MFI) of IL-17 in Tregs in AOSD patients with and without sore throat. (b): The MFI of IL-4 in Tregs in those with and without pleuritis. The Mann-Whitney U test was used for comparisons.